Interleukin-1 (IL-1) Inhibitors Prior Authorization with Quantity Limit Program Summary
Interleukin (IL)-1 Inhibitors Prior Authorization with Quantity Limit
TARGETED AGENT(S) Arcalyst® (rilonacept) Ilaris® (canakinumab)
QUANTITY LIMIT FOR PRIOR AUTHORIZATION Brand (generic) GPI Multisource Quantity Code Limit (per day or as listed) Arcalyst (rilonacept) 220 mg single-use vial 66450060002120 M, N, O, or Y 8 vials/28 days Ilaris (canakinumab) 150 mg/mL single-use 66460020002015 M, N, O, or Y 2 vials/28 days vial 150 mg single-use vial 66460020002115 M, N, O, or Y 2 vials/28 days
PRIOR AUTHORIZATION CRITERIA FOR APPROVAL Initial Evaluation Arcalyst (rilonacept) will be approved when ALL of the following are met: 1. ONE of the following: a. BOTH of the following: i. The patient has ONE of the following indications: 1. Cryopyrin Associated Periodic Syndrome (CAPS) OR 2. Familial Cold Auto-Inflammatory Syndrome (FCAS) OR 3. Muckle-Wells Syndrome (MWS) AND ii. BOTH of the following: 1. The patient has elevated pretreatment serum inflammatory markers (C-reactive protein/serum amyloid A) AND 2. The patient has at least TWO of the following symptoms typical for CAPS: a. Urticaria-like rash b. Cold/stress triggered episodes c. Sensorineural hearing loss d. Musculoskeletal symptoms of arthralgia/arthritis/myalgia e. Chronic aseptic meningitis f. Skeletal abnormalities of epiphyseal overgrowth/frontal bossing OR b. BOTH of the following: i. The patient has a diagnosis of deficiency of interleukin-1 receptor antagonist AND ii. The requested agent is being used for maintenance of remission Boeing_PS_IL-1_Inhibitors_PA_QL_ProgSum_AR0621 Page 1 of 6
© Copyright Prime Therapeutics LLC. 06/2021 All Rights Reserved Effective: 08/01/2021 OR c. The patient has a diagnosis of recurrent pericarditis AND ONE of the following i. BOTH of the following: 1. The patient has tried and had an inadequate response to at least a 6- month trial of colchicine in combination with an NSAID used in the treatment of recurrent pericarditis AND 2. The patient has tried and had an inadequate response to systemic corticosteroids used in the treatment of recurrent pericarditis OR ii. The patient has an intolerance or hypersensitivity to colchicine in combination with NSAIDs AND systemic corticosteroids used in the treatment of recurrent pericarditis OR iii. The patient has tried and had an inadequate response to an oral immunosuppressant (i.e., azathioprine, methotrexate, mycophenolate) used in the treatment of recurrent pericarditis OR iv. The patient has an intolerance or hypersensitivity to oral immunosuppressants used in the treatment of recurrent pericarditis OR v. The patient has an FDA labeled contraindication to colchicine, systemic corticosteroids, AND oral immunosuppressants used in the treatment of recurrent pericarditis OR d. The patient has another FDA approved indication for the requested agent OR e. The patient has another indication that is supported in compendia for the requested agent AND 2. ONE of the following: a. The patient’s age is within FDA labeling for the requested indication for the requested agent OR b. The prescriber has provided information in support of using the requested agent for the patient’s age AND 3. The prescriber is a specialist in the area of the patient’s diagnosis (e.g., allergist, immunologist, pediatrician, cardiologist) or the prescriber has consulted with a specialist in the area of the patient’s diagnosis AND 4. The patient will NOT be using the requested agent in combination with another biologic immunomodulator agent or Zeposia AND 5. The patient does NOT have any FDA labeled contraindications to the requested agent AND 6. ONE of the following: a. The requested quantity (dose) does NOT exceed the program quantity limit OR b. ALL of the following: i. The requested quantity (dose) is greater than the program quantity limit AND ii. The requested quantity (dose) does NOT exceed the maximum FDA labeled dose for the requested indication AND
Boeing_PS_IL-1_Inhibitors_PA_QL_ProgSum_AR0621 Page 2 of 6
© Copyright Prime Therapeutics LLC. 06/2021 All Rights Reserved Effective: 08/01/2021 iii. The requested quantity (dose) cannot be achieved with a lower quantity of a higher strength that does not exceed the program quantity limit OR c. ALL of the following: i. The requested quantity (dose) is greater than the program quantity limit AND ii. The requested quantity (dose) is greater than the maximum FDA labeled dose for the requested indication AND iii. The prescriber has provided information in support of therapy with a higher dose for the requested indication
Length of Approval: 12 months
Compendia Allowed: AHFS or DrugDex 1, 2a or 2b level of evidence
Ilaris (canakinumab) will be approved when ALL of the following are met: 1. ONE of the following: a. The patient’s age is within FDA labeling for the requested indication for the requested agent OR b. The prescriber has provided information in support of using the requested agent for the patient’s age AND 2. ONE of the following: a. BOTH of the following i. The patient has one of the following indications: 1. Cryopyrin Associated Periodic Syndrome (CAPS) OR 2. Familial Cold Auto-Inflammatory Syndrome (FCAS) OR 3. Muckle-Wells Syndrome (MWS) AND ii. BOTH of the following: 1. The patient has elevated pretreatment serum inflammatory markers (C-reactive protein/serum amyloid A) AND 2. The patient has at least TWO of the following symptoms typical for CAPS: a. Urticaria-like rash b. Cold/stress triggered episodes c. Sensorineural hearing loss d. Musculoskeletal symptoms of arthralgia/arthritis/myalgia e. Chronic aseptic meningitis f. Skeletal abnormalities of epiphyseal overgrowth/frontal bossing OR b. The patient has a diagnosis of Familial Mediterranean Fever (FMF) AND ONE of the following: i. The patient has tried and had an inadequate response to colchicine for at least 6 months OR ii. The patient has an intolerance or hypersensitivity to colchicine OR iii. The patient has an FDA labeled contraindication to colchicine Boeing_PS_IL-1_Inhibitors_PA_QL_ProgSum_AR0621 Page 3 of 6
© Copyright Prime Therapeutics LLC. 06/2021 All Rights Reserved Effective: 08/01/2021 OR c. The patient has a diagnosis of Hyperimmunoglobulin D Syndrome (HIDS) or Mevalonate Kinase Deficiency (MKD) OR d. The patient has a diagnosis of Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) OR e. The patient has a diagnosis of Active systemic juvenile idiopathic arthritis (SJIA) AND BOTH of the following: i. The patient has documented active systemic features (e.g., ongoing fever for at least 2 weeks, evanescent erythematous rash, generalized lymphadenopathy, ≥1 joint with active arthritis, hepatomegaly, splenomegaly, serositis) AND ii. ONE of the following: 1. The patient has tried and had an inadequate response to TWO of the following drug classes: a. DMARDs (i.e., methotrexate, leflunomide) for at least a 3- month trial OR b. systemic glucocorticoids (oral or IV) for at least a 3-month trial OR c. NSAIDs for at least a 1-month trial OR 2. The patient has an intolerance or hypersensitivity to TWO of the prerequisite drug classes OR 3. The patient has an FDA labeled contraindication to ALL prerequisite agents OR 4. The patient’s medication history indicates use of another biologic immunomodulator agent that is FDA labeled or supported in DrugDex with 1 or 2a level of evidence or AHFS for the treatment of SJIA OR f. The patient has a diagnosis of Adult onset Still’s disease and BOTH of the following: i. ONE of the following: 1. The patient has tried and had an inadequate response to at least ONE corticosteroid OR 2. The patient has an intolerance or hypersensitivity to ONE corticosteroid OR 3. The patient has an FDA labeled contraindication to ALL corticosteroids AND ii. ONE of the following: 1. The patient has tried and had an inadequate response to methotrexate OR 2. The patient has an intolerance or hypersensitivity to methotrexate OR 3. The patient has an FDA labeled contraindication to methotrexate OR g. The patient has another FDA approved indication for the requested agent Boeing_PS_IL-1_Inhibitors_PA_QL_ProgSum_AR0621 Page 4 of 6
© Copyright Prime Therapeutics LLC. 06/2021 All Rights Reserved Effective: 08/01/2021 OR h. The patient has another indication that is supported in compendia for the requested agent AND 3. The prescriber is a specialist in the area of the patient’s diagnosis (e.g., allergist, immunologist, pediatrician, rheumatologist) or the prescriber has consulted with a specialist in the area of the patient’s diagnosis AND 4. The patient will NOT be using the requested agent in combination with another biologic immunomodulator agent or Zeposia AND 5. The patient does NOT have any FDA labeled contraindications to the requested agent AND 6. ONE of the following: a. The requested quantity (dose) does NOT exceed the program quantity limit OR b. ALL of the following: i. The requested quantity (dose) is greater than the program quantity limit AND ii. The requested quantity (dose) does NOT exceed the maximum FDA labeled dose for the requested indication AND iii. The requested quantity (dose) cannot be achieved with a lower quantity of a higher strength that does not exceed the program quantity limit OR c. ALL of the following: i. The requested quantity (dose) is greater than the program quantity limit AND ii. The requested quantity (dose) is greater than the maximum FDA labeled dose for the requested indication AND iii. The prescriber has provided information in support of therapy with a higher dose for the requested indication
Length of Approval: 12 months
Compendia Allowed: AHFS or DrugDex 1, 2a or 2b level of evidence
Renewal Evaluation Target Agent(s) will be approved when ALL of the following are met: 1. The patient has been previously approved for the requested agent through plan’s Prior Authorization process AND 2. The patient has had clinical benefit with the requested agent AND 3. The prescriber is a specialist in area of the patient’s diagnosis (e.g., allergist, immunologist, pediatrician, rheumatologist, cardiologist) or the prescriber has consulted with a specialist in the area of the patient’s diagnosis AND 4. The patient will NOT be using the requested agent in combination with another biologic immunomodulator agent or Zeposia AND 5. The patient does NOT have any FDA labeled contraindications to the requested agent AND 6. ONE of the following: a. The requested quantity (dose) does NOT exceed the program quantity limit Boeing_PS_IL-1_Inhibitors_PA_QL_ProgSum_AR0621 Page 5 of 6
© Copyright Prime Therapeutics LLC. 06/2021 All Rights Reserved Effective: 08/01/2021 OR b. ALL of the following: i. The requested quantity (dose) is greater than the program quantity limit AND ii. The requested quantity (dose) does NOT exceed the maximum FDA labeled dose for the requested indication AND iii. The requested quantity (dose) cannot be achieved with a lower quantity of a higher strength that does not exceed the program quantity limit OR c. ALL of the following: i. The requested quantity (dose) is greater than the program quantity limit AND ii. The requested quantity (dose) is greater than the maximum FDA labeled dose for the requested indication AND iii. The prescriber has provided information in support of therapy with a higher dose for the requested indication
Length of Approval: 12 months
Boeing_PS_IL-1_Inhibitors_PA_QL_ProgSum_AR0621 Page 6 of 6
© Copyright Prime Therapeutics LLC. 06/2021 All Rights Reserved Effective: 08/01/2021